Related Experiment Video
Updated: Feb 24, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
An Infant With Epilepsy and Recurrent Hemiplegia due to Compound Heterozygous Variants in ATP1A2
Colin Wilbur1, Sarah E Buerki1, Ilaria Guella2
1Division of Neurology, Department of Pediatrics, University of British Columbia and BC Children's Hospital, Vancouver, British Columbia, Canada.
Insights
Compound heterozygous ATP1A2 variants can cause a spectrum of neurological events, including epilepsy and hemiplegia. Genetic diagnosis guided successful treatment with flunarizine, preventing further hemiplegic episodes.
Area of Science:
- Neurogenetics
- Molecular Neurology
Background:
- ATP1A2 gene variants are linked to familial hemiplegic migraine.
- Phenotypes also include alternating hemiplegia of childhood and epilepsy.
Observation:
- A boy presented with epilepsy, paroxysmal events, and recurrent hemiplegia.
- MRI showed unilateral cortical edema during hemiplegia, followed by mild hemiparesis.
Findings:
- Whole-exome sequencing revealed compound heterozygous ATP1A2 variants: a pathogenic p.Arg548Cys and a novel uncertain p.Arg1008Trp.
- Treatment with flunarizine halted hemiplegic episodes post-diagnosis.
Implications:
- This case highlights the broad phenotypic spectrum of ATP1A2 variants.
- It underscores the importance of genetic testing in diagnosing and managing complex paroxysmal neurological disorders.
Background:
Pathogenic heterozygous variants in the ATP1A2 gene have most commonly been associated with familial hemiplegic migraine. However, a wide spectrum of phenotypes that include alternating hemiplegia of childhood and epilepsy have been described.
Patient Description:
We describe a boy who presented at age three months with a complex phenotype that included epilepsy, nonepileptic paroxysmal events, and recurrent hemiplegia. Magnetic resonance imaging demonstrated unilateral cortical edema during a severe episode of hemiplegia that was followed by a persistent mild hemiparesis.
Results:
Whole-exome sequencing identified a previously reported ATP1A2 missense variant (p.Arg548Cys) classified as pathogenic and a novel missense variant (p.Arg1008Trp) classified as a variant of uncertain significance. After this genetic diagnosis, treatment with flunarizine was initiated and no further episodes of hemiplegia have occurred.
Conclusions:
This is only the second report of compound heterozygosity of the ATP1A2 gene. It demonstrates the spectrum of paroxysmal neurological events that can arise as a result of ATP1A2 variants, with unique features overlapping alternating hemiplegia of childhood, hemiplegic migraine, and epilepsy. This child illustrates the diagnostic challenges that these disorders can present and the importance of genetic diagnosis in guiding management.
More Related Videos
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
Related Concept Videos
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Inborn Errors of Metabolism
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
ATP Synthase: Mechanism
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...